Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19319360 | CANNABINOID ANALOGS, FORMULATIONS, AND METHODS OF USE | September 2025 | January 2026 | Allow | 5 | 0 | 1 | Yes | No |
| 18709340 | FLUORINE-CONTAINING PYRIMIDINE COMPOUNDS, HARMFUL FUNGUS CONTROL AGENT, AND METHOD FOR PRODUCING FLUORINE-CONTAINING PYRIMIDINE COMPOUNDS | December 2024 | October 2025 | Allow | 17 | 1 | 0 | No | No |
| 18792976 | NATURAL AND SYNTHETIC CANNABINOIDS AS FLUORESCENT TAGS; COMPOSITIONS, METHODS, AND APPLICATIONS | August 2024 | April 2025 | Allow | 8 | 0 | 1 | Yes | No |
| 18404409 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | January 2024 | August 2025 | Allow | 19 | 2 | 1 | No | No |
| 18576128 | NITRILE SUMO INHIBITORS AND USES THEREOF | January 2024 | November 2025 | Allow | 22 | 1 | 0 | No | No |
| 18379351 | Pyrrolidine Main Protease Inhibitors as Antiviral Agents | October 2023 | October 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18377540 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS | October 2023 | October 2025 | Allow | 25 | 0 | 1 | Yes | No |
| 18367650 | PYRROLO[3,2-C][1,7]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 2 | 1 | 0 | No | No |
| 18231103 | ANTIPROLIFERATIVE SELENATED-FOLATE HYBRIDS | August 2023 | September 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18263513 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | July 2023 | December 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18271623 | COSMETIC COMPOUNDS HAVING TWO LINKED MALEIMIDE GROUPS, COSMETIC PREPARATIONS, AND METHOD FOR TREATMENT OF KERATIN MATERIALS | July 2023 | March 2026 | Allow | 32 | 1 | 1 | Yes | No |
| 18215530 | CRYSTAL FORMS OF CRENOLANIB AND METHODS OF USE THEREOF | June 2023 | August 2025 | Allow | 25 | 0 | 1 | Yes | No |
| 18212061 | SYNTHESIS OF CANNABIDIOL AND ANALOGS THEREOF, AND RELATED COMPOUNDS, FORMULATIONS, AND METHODS OF USE | June 2023 | January 2026 | Abandon | 31 | 1 | 1 | No | No |
| 18036140 | PREPARATION METHOD FOR CANNFLAVIN COMPOUNDS | May 2023 | March 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18142789 | ANTIMICROBIAL COMPOUNDS AND NANOSTRUCTURES | May 2023 | September 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 18250647 | [(1,5-DIHETEROARYL-1H-1,2,4-TRIAZOL-3-YL)OXY] ACETIC ACID DERIVATIVES AS SAFENERS FOR THE PROTECTION OF USEFUL PLANTS AND CROP PLANTS | April 2023 | December 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 18247521 | LACTAM COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | March 2023 | January 2026 | Allow | 34 | 0 | 1 | Yes | No |
| 18167974 | CRYSTALLIZATION OF CANNABINOIDS | February 2023 | February 2026 | Allow | 36 | 0 | 1 | Yes | No |
| 18080812 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, RETARDATION FILM, METHOD FOR PRODUCING RETARDATION FILM, TRANSFER LAMINATE, OPTICAL MEMBER, METHOD FOR PRODUCING OPTICAL MEMBER, AND DISPLAY DEVICE | December 2022 | August 2025 | Allow | 32 | 1 | 0 | No | No |
| 18062484 | Monoacylglycerol Lipase Modulators | December 2022 | September 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 18008044 | METHOD FOR PREPARING DIHYDROQUERCETIN | December 2022 | April 2023 | Allow | 5 | 0 | 0 | No | No |
| 18008099 | SEMI SYNTHETIC METHOD FOR DIHYDROQUERCETIN | December 2022 | August 2023 | Allow | 9 | 1 | 0 | No | No |
| 17998972 | XANTHENE DERIVATIVES, MIXTURES COMPRISING SAME, MANUFACTURING METHOD AND CORRESPONDING USES | November 2022 | January 2026 | Allow | 38 | 1 | 0 | Yes | No |
| 17924956 | TRIAZINE AND PYRIMIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | November 2022 | August 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17918880 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | October 2022 | December 2025 | Allow | 38 | 1 | 1 | No | No |
| 17963942 | DEUTERATED SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS AND METHODS AND USES THEREOF | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17917629 | MICROBIOCIDAL QUINOLINE DIHYDRO-(THIAZINE)OXAZINE DERIVATIVES | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | Yes | No |
| 17796542 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | July 2022 | November 2025 | Allow | 39 | 1 | 0 | No | No |
| 17789956 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | June 2022 | March 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17786544 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | June 2022 | March 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17786349 | SUBSTITUTED THIOPHENE CARBOXAMIDES AND DERIVATIVES THEREOF AS MICROBICIDES | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17786151 | SUBSTITUTED THIOPHENE CARBOXAMIDES, THIOPHENE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | June 2022 | January 2026 | Allow | 43 | 1 | 1 | Yes | No |
| 17776331 | HERBICIDAL THIAZOLE COMPOUNDS | May 2022 | February 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17771732 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | April 2022 | September 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17767749 | 2,6-DIOXO-3,6-DIHYDROPYRIMIDINE COMPOUND, AGRICULTURAL AND HORTICULTURAL BACTERICIDE, NEMATICIDE, AND MEDICAL AND VETERINARY ANTIFUNGAL AGENT | April 2022 | October 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17640822 | CANNABIGEROL PROLINE COCRYSTALS | March 2022 | February 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17666943 | USE OF AN AMPHIDINOL FOR ITS FUNGICIDAL AND/OR BACTERICIDAL ACTIVITY ON FUNGI, OOMYCETES AND/OR PATHOGENIC BACTERIA OF PLANTS AND CROP SEEDS | February 2022 | August 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17649328 | CINNAMALDEHYDE DERIVATIVE COMPOUNDS AND METHODS OF USE FOR CINNAMALDEHYDE DERIVATIVE COMPOUNDS NICOTINE CESSATION | January 2022 | August 2023 | Allow | 19 | 1 | 0 | No | No |
| 17628664 | SUBSTITUTED PYRIMIDINEDIONE COMPOUNDS AND USES THEREOF | January 2022 | December 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17626205 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMERS DISEASE | January 2022 | November 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17550071 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | December 2021 | October 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17548837 | MANIPULATING HYDROPHILICITY OF CONVENTIONAL DYE MOLECULES FOR WATER TRACER APPLICATIONS | December 2021 | March 2023 | Allow | 15 | 0 | 1 | Yes | No |
| 17532215 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | November 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
| 17526596 | ANTIMICROBIAL COMPOUNDS AND NANOSTRUCTURES | November 2021 | January 2023 | Allow | 15 | 0 | 0 | No | No |
| 17510817 | CANNABINOID GLYCOSIDES AND USES THEREOF | October 2021 | September 2023 | Abandon | 23 | 2 | 1 | Yes | No |
| 17602700 | PHARMACOLOGICAL MITIGATION OF LATE-STAGE TOXEMIA | October 2021 | November 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17380396 | Flash and Glow 1,2-Dioxetanes | July 2021 | December 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17334432 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | May 2021 | February 2023 | Allow | 21 | 1 | 0 | No | No |
| 17326433 | CRYSTAL FORMS OF CRENOLANIB AND METHODS OF USE THEREOF | May 2021 | March 2023 | Allow | 21 | 0 | 1 | No | No |
| 17255231 | DEUTERATED MGL-3196 COMPOUND AND USE THEREOF | May 2021 | January 2026 | Abandon | 60 | 4 | 0 | Yes | No |
| 17307656 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | May 2021 | December 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17222611 | CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS | April 2021 | February 2023 | Allow | 22 | 0 | 1 | No | No |
| 17212173 | METHOD FOR HIGHLY SELECTIVE CONVERSION OF CBD TO DELTA-8 THC | March 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17189803 | Compositions and Methods for Treating Retinal Degradation | March 2021 | February 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17263141 | METHOD FOR DECOMPOSING FLAVONOID GLYCOSIDE AND METHOD FOR PRODUCING FLAVONOID | January 2021 | September 2023 | Allow | 32 | 2 | 0 | Yes | No |
| 17148615 | PRODUCTION OF PROTOANEMONIN BY OXIDATION OF LEVULINIC ACID OR ANGELICALACTONE ISOMERS | January 2021 | April 2023 | Abandon | 27 | 2 | 0 | No | No |
| 17144302 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | January 2021 | July 2023 | Abandon | 30 | 2 | 0 | Yes | No |
| 17132313 | Monoacylglycerol Lipase Modulators | December 2020 | September 2022 | Allow | 20 | 2 | 1 | Yes | No |
| 17058623 | DIOXETANE COMPOUNDS AND THEIR USE FOR THE DETECTION OF MICROORGANISMS | November 2020 | December 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 16950357 | PROCESS FOR THE PRODUCTION OF CANNABIDIOL AND DELTA-9-TETRAHYDROCANNABINOL | November 2020 | February 2025 | Abandon | 51 | 6 | 0 | No | Yes |
| 17046004 | A SUBSTITUTED OXOPYRIDINE DERIVATIVE | October 2020 | September 2023 | Allow | 36 | 0 | 0 | Yes | No |
| 16980626 | METHOD FOR PRODUCING GLYCOLIDE | September 2020 | October 2022 | Allow | 25 | 3 | 0 | No | No |
| 16977638 | IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES | September 2020 | November 2025 | Allow | 60 | 7 | 1 | Yes | No |
| 16904754 | PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE | June 2020 | May 2023 | Allow | 34 | 2 | 0 | Yes | No |
| 16764444 | STRIGOLACTONE DERIVATIVES | May 2020 | June 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16651577 | NOVEL SALTS OF 7-METHYL-2-[4-METHYL-6-[4-(TRIFLUOROMETHYL)- PHENYL]PYRIMIDIN-2-YL]-1,7-DIAZASPIRO[4.4|NONAN-6-ONE | March 2020 | August 2023 | Abandon | 40 | 2 | 1 | Yes | No |
| 16810626 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | March 2020 | March 2026 | Allow | 60 | 7 | 1 | Yes | No |
| 16622033 | Silole and Germole Fused Ring Photochromic Compounds | December 2019 | April 2023 | Allow | 40 | 2 | 1 | No | No |
| 16464860 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | May 2019 | April 2021 | Allow | 23 | 1 | 1 | No | No |
| 16343748 | HETEROCYCLIC CONTAINING CYCLOPROPYL FXR MODULATORS | April 2019 | August 2020 | Allow | 16 | 1 | 0 | Yes | No |
| 16329992 | CRYSTAL FORMS OF VALSARTAN DISODIUM SALT | March 2019 | May 2020 | Allow | 14 | 0 | 1 | Yes | No |
| 16313778 | IMIDAZOPYRIDOPYRIMIDINE DERIVATIVE COMPOUND AND USE THEREOF | December 2018 | April 2020 | Allow | 15 | 1 | 0 | Yes | No |
| 16098202 | HYDROXYALKYL-SUBSTITUTED HETEROARYLTRIAZOLE DERIVATIVES AND USES THEREOF | November 2018 | August 2019 | Allow | 10 | 0 | 0 | Yes | No |
| 15900117 | METHOD FOR SYNTHESIZING TETRAHYDROISOQUINOLINE THIAZOLIDINE | February 2018 | September 2018 | Allow | 7 | 0 | 0 | No | No |
| 15751273 | Indazolyl-oxo-isothiazole compounds | February 2018 | September 2018 | Allow | 7 | 0 | 0 | Yes | No |
| 15747313 | EPOTHILONE B AND DICTYOSTATIN ANALOGS, THEIR PREPARATION AND USE | January 2018 | January 2020 | Allow | 24 | 2 | 1 | Yes | No |
| 15869368 | FUMIGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | January 2018 | October 2018 | Allow | 9 | 0 | 0 | No | No |
| 15559516 | P-TOLUENESULFONATE FOR MEK KINASE INHIBITOR, AND CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | September 2017 | July 2018 | Allow | 10 | 0 | 0 | No | No |
| 15550783 | ISOTHIOCYANATE COMPOUNDS AND ISOTHIOCYANATE XPO1 PROTEIN INHIBITOR DRUGS THEREOF | August 2017 | January 2019 | Allow | 17 | 2 | 0 | Yes | No |
| 15507079 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | February 2017 | March 2019 | Allow | 25 | 1 | 1 | No | No |
| 15434454 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ABERRANT LIPOGENIC SIGNALING | February 2017 | January 2018 | Allow | 11 | 0 | 1 | No | No |
| 15503944 | METHOD FOR THE PHOSGENATION OF COMPOUNDS COMPRISING HYDROXYL, THIOL, AMINO AND/OR FORMAMIDE GROUPS | February 2017 | June 2018 | Allow | 16 | 1 | 1 | No | No |
| 15399071 | FUMIGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | January 2017 | October 2017 | Allow | 9 | 0 | 0 | No | No |
| 15029452 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | April 2016 | April 2017 | Allow | 12 | 0 | 0 | Yes | No |
| 15081498 | Crystal Form of Dabrafenib and Preparation Method and Use Thereof | March 2016 | August 2016 | Allow | 4 | 1 | 0 | No | No |
| 15075976 | PROCESS FOR REMOVING CATIONS FROM AN ISOPHORONENITRILE PRODUCT MIXTURE | March 2016 | September 2017 | Allow | 18 | 1 | 0 | No | No |
| 14916859 | CRYSTALLINE 4-(3S-(1R-(1-NAPTHYL)ETHYLAMINO)PYRROLIDIN-1-YL)PHENYLACETIC ACID | March 2016 | February 2017 | Allow | 11 | 0 | 0 | Yes | No |
| 15051077 | DRUG REPOSITIONING: UREASE INHIBITORY ACTIVITY OF (2S)-1-[(2S)-2-METHYL-3-SULFANYLPROPANOYL]PYRROLIDINE-2-CARBOXYLIC ACID (CAPTOPRIL) | February 2016 | February 2017 | Allow | 12 | 2 | 0 | Yes | No |
| 14907109 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | January 2016 | March 2017 | Allow | 14 | 1 | 0 | No | No |
| 15001484 | METHOD FOR PREPARING IDO INHIBITOR EPACADOSTAT | January 2016 | December 2016 | Allow | 11 | 0 | 0 | No | No |
| 14906206 | N-hydroxybenzamides as HDAC inhibitors for the treatment of parasitic diseases | January 2016 | June 2018 | Allow | 29 | 3 | 1 | No | No |
| 14892298 | SYNTHESIS OF COUMALIC ACID | November 2015 | December 2016 | Allow | 13 | 0 | 1 | No | No |
| 14923875 | PROCESS FOR THE PREPARATION OF ERLOTINIB | October 2015 | June 2016 | Allow | 8 | 0 | 0 | No | No |
| 14876072 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | October 2015 | February 2017 | Allow | 17 | 1 | 1 | Yes | No |
| 14770648 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | August 2015 | October 2016 | Allow | 13 | 1 | 0 | No | No |
| 14769567 | TRICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | August 2015 | August 2017 | Allow | 24 | 1 | 1 | No | No |
| 14768218 | PHENOLIC EPOXY COMPOUNDS | August 2015 | November 2016 | Allow | 27 | 1 | 1 | No | No |
| 14761270 | ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | July 2015 | October 2016 | Allow | 15 | 1 | 1 | Yes | No |
| 14794073 | Crystal Form of Dabrafenib and Preparation Method and Use Thereof | July 2015 | March 2016 | Allow | 9 | 1 | 1 | No | No |
| 14744103 | Benzamide-Containing Compounds and Their Use in the Treatment of Pain | June 2015 | January 2017 | Allow | 19 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RODRIGUEZ-GARCIA, VALERIE.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 71.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner RODRIGUEZ-GARCIA, VALERIE works in Art Unit 1621 and has examined 166 patent applications in our dataset. With an allowance rate of 92.8%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 26 months.
Examiner RODRIGUEZ-GARCIA, VALERIE's allowance rate of 92.8% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by RODRIGUEZ-GARCIA, VALERIE receive 1.37 office actions before reaching final disposition. This places the examiner in the 20% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RODRIGUEZ-GARCIA, VALERIE is 26 months. This places the examiner in the 75% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -0.6% benefit to allowance rate for applications examined by RODRIGUEZ-GARCIA, VALERIE. This interview benefit is in the 11% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 31.6% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 47.1% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 71.4% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 27.9% are granted (fully or in part). This grant rate is in the 15% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 33.1% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.